-

Morepen Starts Commercial Supplies Under its Rs. 825 Crore CDMO Mandate; First Rs. 50 Crore Dispatch Already Completed in Q1FY2026-27
Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced Rs. 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs. 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation…
-

Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. This milestone reflects the Company’s long-range quality strategy focused on sustained compliance, continuous audit readiness, and operational effectiveness. Through robust governance, quality culture initiatives, workforce development, and…
-
Maiva Pharma Inaugurates New State-of-the-Art Sterile Injectable Manufacturing Facility at Shoolagiri, India
Six manufacturing lines to enable production of diverse sterile injectable formats, from vials and pre-filled syringes to cartridges, suspensions and lyophilized formulations Bengaluru, Karnataka, India Maiva Pharma, a leading global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) specialising in sterile injectables, today inaugurated its new manufacturing facility at Shoolagiri, Tamil Nadu,…
-

Akums Reports Q2 FY26 Results; Strengthens International Presence
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26. The CDMO segment remained the key contributor with revenue of Rs. 804 crore. Volumes for the CDMO vertical grew 7% y-o-y, as against muted industry volume growth, reflecting…
-

Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.






